Effects of haloperidol on cognition in schizophrenia patients depend on baseline performance: A saccadic eye movement study

Publication year: 2011
Source: Progress in Neuro-Psychopharmacology and Biological Psychiatry, In Press, Accepted Manuscript, Available online 13 June 2011

Shelly L., Babin , Ashley J., Hood , Adel A., Wassef , Nina G., Williams , Saumil S., Patel , …

Schizophrenic patients are heterogeneous with respect to voluntary eye movement performance, with some showing impairment (e.g., high antisaccade error rates) and others having intact performance. To investigate how this heterogeneity may correlate with different cognitive outcomes after treatment, we used a prosaccade and antisaccade task to investigate the effects of haloperidol in schizophrenic subjects at three time points: baseline (before medication), 3–5days post-medication, and 12–14days post-medication. We also investigated changes on the Stroop Task and the Positive and Negative Syndrome Scale (PANSS) in these same subjects. Results were compared to matched controls. When considered as a single patient group, haloperidol…

 Research highlights: ► Changes in symptom reduction may not parallel changes in cognitive performance ► Voluntary eye movements may be a sensitive measure of cognitive change ► Schizophrenia patients may have differential cognitive responses to typical antipsychotics depending on whether their cognition is initially intact or impaired. These concepts are crucial to optimal evaluation and treatment of schizophrenia patients given cognition is the strongest predictor of long-term prognosis.